Maxim Group set a $5.00 price objective on OncoSec Medical (NASDAQ:ONCS) in a report released on Thursday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

“Oncosec announced that the P2b study (PISCES/KEYNOTE-695) in late-stage melanoma evaluating TAVO (DNA-based IL-12, intratumoral) + Keytruda has dosed the first patient.”,” the firm’s analyst commented.

ONCS has been the subject of several other reports. ValuEngine raised OncoSec Medical from a strong sell rating to a sell rating in a report on Thursday, November 9th. HC Wainwright reissued a buy rating and issued a $6.00 price objective on shares of OncoSec Medical in a report on Thursday, November 9th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $5.33.

Shares of OncoSec Medical (ONCS) opened at $1.59 on Thursday. OncoSec Medical has a fifty-two week low of $0.88 and a fifty-two week high of $2.95.

OncoSec Medical (NASDAQ:ONCS) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05). equities research analysts expect that OncoSec Medical will post -0.86 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Maxim Group Analysts Give OncoSec Medical (ONCS) a $5.00 Price Target” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Analyst Recommendations for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with's FREE daily email newsletter.